Targeting the mucosal immune system of the genital tract (GT) with subunit vaccines failed to induce potent and durable local immune response, crucial for protection against many sexually transmitted viral (STV) pathogens, including herpes simplex virus type 2 (HSV-2) that causes genital herpes. In this study, we investigated the potential of a novel lipopeptide/adenovirus type 5 (Lipo/rAdv5) prime/boost mucosal vaccine for induction of CD8+ T cell immunity to protect the female genital tract from herpes. The findings indicate that targeting the GT with a Lipo/rAdv5 prime/boost vaccine elicits a potent and long-lasting mucosal CD8+ T cell protective immunity against sexually transmitted herpes infection and disease.
Dr. Huma Qureshi, from UC Davis, has recently joined our lab. She worked as a post-doctoral fellow in Dr. Christopher Miller’s lab for last 4 years. She was involved in pre-clinical development studies using an adenovirus vector to vaccinate against HIV and AIDS. As An Assistant Specialist, Dr. Qureshi will now be involved in vaccine development against ocular and genital herpes. She will focus on studying effector and regulatory T cell responses against newly discovered herpes epitopes, during both acute and latent infection, and in both animal models and humans.
For an update on herpes vaccine development; check out our recent clinical review in Clinical and Developmental Immunology Journal: Chentoufi AA, Kritzer E, Yu DM, Nesburn AB, BenMohamed L. Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown. Clin Dev Immunol. 2012; 2012:187585.